0.5 mg
Trade Name
Bergo
Tablet
Request Type
New Registration
Drug Type
Generic(Multisource) Drug
Approval Date
SFDA Approved Use
Inhibition/suppression of physiological lactation
Cabergoline is indicated for the inhibition of physiological lactation soon after delivery and for suppression of already established lactation:
1. After parturition, when the mother elects not to breast feed the infant or when breast feeding is contraindicated due to medical reasons related to the mother or the new-born.
2. After stillbirth or abortion.
Cabergoline prevents/suppresses physiological lactation by inhibiting prolactin secretion.
Treatment of hyperprolactinaemic disorders
Cabergoline is indicated for the inhibition of physiological lactation soon after delivery and for suppression of already established lactation:
1. After parturition, when the mother elects not to breast feed the infant or when breast feeding is contraindicated due to medical reasons related to the mother or the new-born.
2. After stillbirth or abortion.
Cabergoline prevents/suppresses physiological lactation by inhibiting prolactin secretion.
Treatment of hyperprolactinaemic disorders